Alvotech will announce its Q2 2025 financial results on August 13, followed by a conference call on August 14.
Quiver AI Summary
Alvotech, a biotech company focused on developing and manufacturing biosimilar medicines, announced that it will release its financial results for the first half of 2025 on August 13, after U.S. markets close. A conference call to discuss the results and business updates will take place on August 14 at 8:00 am EDT, with live audio available on Alvotech's investor portal. The company aims to be a leader in the biosimilar market, currently having two approved products and a pipeline of nine candidates targeting various health conditions. Alvotech has established strategic partnerships globally to enhance its market presence, covering regions including the U.S., Europe, Asia, and South America. For additional details, stakeholders can access the investor portal and various social media platforms.
Potential Positives
- Alvotech is scheduled to release its financial results for the first half of 2025, indicating transparency and commitment to informing stakeholders about its performance.
- The company will host a conference call to discuss financial results and recent business highlights, providing an opportunity for investors and analysts to engage directly with management.
- Alvotech has two approved and marketed biosimilars, showcasing its capability and success in the competitive biotech industry.
- The company has a robust pipeline with nine disclosed biosimilar candidates, highlighting its potential for future growth and expansion in treating various medical conditions.
Potential Negatives
- There is a lack of clarity on the financial performance leading up to the upcoming earnings release, which may raise concerns among investors regarding recent company performance.
- The announcement of financial results and a conference call may indicate that the company has not achieved its financial goals or expectations for the period.
- The extensive reliance on commercial partnerships may highlight a potential weakness in the company's independence and ability to sustain growth solely on its own products.
FAQ
When will Alvotech release its financial results for 2025?
Alvotech will release its financial results for the first half of 2025 on August 13, 2025, after U.S. markets close.
What time is the Alvotech conference call?
The conference call to discuss financial results will take place on August 14, 2025, at 8:00 am EDT.
How can I access the Alvotech conference call webcast?
The webcast can be accessed via Alvotech’s investor portal at https://investors.alvotech.com.
How long will the conference call replay be available?
The archived webcast of the conference call will be available for replay for 90 days after the event.
What biosimilars does Alvotech have on the market?
Alvotech has approved and marketed biosimilars to Humira® and Stelara® in multiple global markets.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 26 institutional investors add shares of $ALVO stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,401,421 shares (+inf%) to their portfolio in Q1 2025, for an estimated $13,551,741
- VANGUARD GROUP INC added 995,538 shares (+31.1%) to their portfolio in Q1 2025, for an estimated $9,626,852
- SCULPTOR CAPITAL LP removed 565,359 shares (-93.3%) from their portfolio in Q1 2025, for an estimated $5,467,021
- MORGAN STANLEY removed 469,680 shares (-31.7%) from their portfolio in Q1 2025, for an estimated $4,541,805
- POINTSTATE CAPITAL LP removed 67,040 shares (-5.4%) from their portfolio in Q1 2025, for an estimated $648,276
- OAKTREE CAPITAL MANAGEMENT LP removed 57,222 shares (-3.0%) from their portfolio in Q1 2025, for an estimated $553,336
- LODBROK CAPITAL LLP removed 25,087 shares (-13.8%) from their portfolio in Q1 2025, for an estimated $242,591
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALVO Analyst Ratings
Wall Street analysts have issued reports on $ALVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for $ALVO, check out Quiver Quantitative's $ALVO forecast page.
Full Release
REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025. Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday, August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio of the conference call will be webcast and available on Alvotech’s investor portal.
Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor portal https://investors.alvotech.com . Specifically, links to access the webcast and instructions to sign in by phone can be found at https://investors.alvotech.com/events/event-details/q2-2025-earnings . The webcast will also be archived and available for replay for 90 days after the event.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit
https://www.alvotech.com
. None of the information on the Alvotech website shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
[email protected]
Please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram , and YouTube .
